[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053549":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":25,"centralContacts":29,"locations":37,"responsibleParty":56,"collaborators":10,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":10,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":10,"enrollmentInfo":67,"targetDuration":10,"studyType":70,"phases":10,"briefSummary":71,"conditions":72,"keywords":10,"overallStatus":40,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"City of Hope Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Chemotherapy response patients.",null,"Responders according to the response evaluation criteria in solid tumors (RECIST).\n\nA panel of DNA methylation, whose specific methylation level is tested DNA from resection tissue with Methylation-specific PCR(MSP)",[13],"Drug: Fluoro Uracil",{"label":15,"type":10,"description":11,"interventionNames":16},"Chemotherapy non-response patients",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","Fluoro Uracil","Esophageal cancer chemotherapy（First line treatment)",[15,9],[24],"Cisplatin",[26],{"name":27,"affiliation":5,"role":28},"Koichi Takiguchi, PhD","PRINCIPAL_INVESTIGATOR",[30,35],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"Ajay Goel, PhD","CONTACT","6262183452","AJGOEL@COH.ORG",{"name":27,"role":32,"phone":33,"phoneExt":10,"email":36},"ktakiguchi@coh.org",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Yamanashi Universiy","RECRUITING","Chūō","Yamanashi","4093898","Japan","JP",{"type":47,"coordinates":48},"Point",[49,50],138.50275,35.59465,{"lat":50,"lon":49},[53],{"name":54,"role":32,"phone":10,"phoneExt":10,"email":55},"Katsutoshi Shoda, PhD","kshoda@yamanashi.ac.jp",{"type":57,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100053549","predicting-postoperative-chemotherapy-efficacy-in-patients-with-esophageal-squamous-cell-carcinoma-100053549",false,"NCT06490003","Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma","Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma by Biopsy Specimens.","Inclusion Criteria:\n\n1. Patients who had histologically confirmed esophageal squamous cell carcinoma.\n2. Patients who had undergone chemotherapy.\n3. Patients receiving initial chemotherapy\n4. Written informed consent following full study information is provided to the patient.\n\nExclusion Criteria:\n\n1. Patients for whom a preoperative biopsy sample cannot be obtained\n2. Patients who cannot assess at 2 months later after chemotherapy.\n3. Patients with multiple cancers.","ALL","20 Years",{"count":68,"type":69},150,"ESTIMATED","OBSERVATIONAL","Esophageal cancer remains a disease with a poor prognosis. Chemotherapy is an important part of its treatment, but there are cases in which chemotherapy is ineffective. The investigators aim to develop a model to predict the response to chemotherapy by DNA methylation of preoperative biopsy specimens to identify the chemotherapy ineffective group.",[73,74,75],"Esophageal Squamous Cell Carcinoma","Chemotherapy Effect","DNA Methylation","2026-07-10",{"date":78,"type":79},"2026-07-13","ACTUAL",{"date":81,"type":79},"2004-06-01",{"date":83,"type":69},"2028-06-18",{"name":5,"class":6},1]